HC Wainwright Issues Pessimistic Estimate for RIGL Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Equities research analysts at HC Wainwright lowered their Q4 2026 earnings per share estimates for shares of Rigel Pharmaceuticals in a research note issued to investors on Friday, November 6th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings per share of $0.87 for the quarter, down from their prior estimate of $0.94. HC Wainwright has a “Buy” rating and a $85.00 price objective on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $2.97 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ FY2027 earnings at $4.78 EPS.

RIGL has been the subject of a number of other reports. Zacks Research downgraded shares of Rigel Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Piper Sandler reaffirmed a “neutral” rating and set a $49.00 price target (up from $40.00) on shares of Rigel Pharmaceuticals in a research note on Monday, August 17th. Weiss Ratings lowered shares of Rigel Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday. Citigroup lifted their price target on shares of Rigel Pharmaceuticals from $83.00 to $86.00 and gave the company a “buy” rating in a report on Monday. Finally, Cantor Fitzgerald boosted their price objective on shares of Rigel Pharmaceuticals from $43.00 to $47.00 and gave the company a “neutral” rating in a research note on Friday, November 6th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $66.75.

Rigel Pharmaceuticals Price Performance

Shares of RIGL stock opened at $43.91 on Monday. The firm’s 50-day simple moving average is $47.66 and its 200-day simple moving average is $37.53. Rigel Pharmaceuticals has a 1-year low of $24.95 and a 1-year high of $52.60. The firm has a market cap of $826.83 million, a P/E ratio of 2.83 and a beta of 1.28.

Rigel Pharmaceuticals (NASDAQ:RIGL) last posted its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.27). Rigel Pharmaceuticals had a net margin of 106.59% and a return on equity of 14.89%. The business had revenue of $80.89 million during the quarter, compared to analysts’ expectations of $80.00 million.

Hedge Funds Weigh In On Rigel Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of RIGL. BlackRock Inc. purchased a new stake in Rigel Pharmaceuticals during the second quarter worth approximately $75,886,000. Assenagon Asset Management S.A. purchased a new position in shares of Rigel Pharmaceuticals in the 3rd quarter valued at $25,793,000. Bank of America Corp DE purchased a new position in shares of Rigel Pharmaceuticals in the 2nd quarter valued at $4,832,000. Globeflex Capital L P purchased a new position in shares of Rigel Pharmaceuticals in the 2nd quarter valued at $4,408,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Rigel Pharmaceuticals during the 2nd quarter valued at $4,233,000. 66.23% of the stock is owned by institutional investors and hedge funds.

Rigel Pharmaceuticals News Roundup

Here are the key news stories impacting Rigel Pharmaceuticals this week:

• Positive Sentiment: Citigroup raised its price target to $86 from $83 and maintained a Buy rating, signaling continued analyst optimism. Citigroup analyst recommendations
• Neutral Sentiment: CEO Raul Rodriguez is scheduled to present a company overview at the Jefferies Global Healthcare Conference on November 17. The appearance may provide investors with updates but is not itself a financial or clinical announcement. Rigel conference announcement
• Neutral Sentiment: A report lists short interest at zero shares and a zero-day short-interest ratio, which indicates no reported short position in the figures provided; the entry’s description of a “significant increase” conflicts with those numbers.
• Negative Sentiment: HC Wainwright reduced its EPS estimates for fiscal 2026 and 2028–2030, including lowering its 2026 forecast to $2.84 from $3.26. The analyst nevertheless kept a Buy rating and an $85 target, so the estimate cuts temper—but do not reverse—the bullish recommendation.
• Negative Sentiment: Rigel’s latest quarterly EPS of $0.65 missed the $0.92 consensus, although revenue of $80.89 million edged past expectations of $80 million. Recent commentary highlighted margin compression alongside top-line momentum, a mixed earnings signal. Q3 top-line momentum and margin compression

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes medicines for people with serious hematologic disorders and cancers. Founded in 1996 and based in South San Francisco, California, the company has focused on treatments that target biological pathways involved in disease. Rigel’s marketed products include Tavalisse (fostamatinib), an oral treatment for adults with chronic immune thrombocytopenia who have had an insufficient response to prior treatment, and Rezlidhia (olutasidenib), an oral therapy for certain adults with relapsed or refractory acute myeloid leukemia containing an IDH1 mutation.